Want to see IN:MEDICAMEQ full AI Analyst Report?

Medicamen Biotech Limited (MEDICAMEQ) Price & Analysis

0 Followers

MEDICAMEQ Stock Chart & Stats

₹366.90

-₹10.20(-1.97%)

At close: Jan 08 4:00 PM EST

₹366.90

-₹10.20(-1.97%)

Day’s Range― - ―

52-Week Range₹210.10 - ₹454.00

Previous CloseN/A

Volume10.37K

Average Volume (3M)2.42K

Market Cap

₹3.67B

Enterprise Value₹3.02K

Total Cash (Recent Filing)₹312.64M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)33.9

Beta1.40

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.36%

Share Statistics

EPS (TTM)8.01

Shares Outstanding13,562,815

10 Day Avg. Volume4,148

30 Day Avg. Volume2,424

Financial Highlights & Ratios

PEG Ratio1.06

Price to Book (P/B)1.08

Price to Sales (P/S)1.51

P/FCF Ratio-7.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recent Revenue RecoveryThe return to revenue growth indicates renewed demand or improved execution across the formulations portfolio. If sustained, stronger sales can improve operating leverage, support broader customer reach, and provide a better base for rebuilding earnings over the next several quarters.

Conservative Balance SheetLow leverage and substantial equity growth provide financial resilience compared with a highly indebted operating model. This structure reduces balance-sheet pressure, preserves flexibility for investment, and gives the company greater capacity to manage volatility in pharmaceutical demand.

Diversified Generic PortfolioA portfolio spanning multiple therapeutic segments can diversify demand across products rather than relying on one medicine or indication. The generic finished-dosage model also gives the company an established platform for serving both domestic and export markets over time.

Bears Say

Persistent Cash BurnRepeated operating cash outflows show that reported business activity is not converting reliably into cash. The FY2026 deterioration increases dependence on working-capital release, external funding, or other financing, potentially limiting investment capacity and weakening financial flexibility.

Weaker ProfitabilityDeclining net income despite the latest revenue recovery points to weaker earnings quality and less reliable profit conversion. Sustained pressure on profitability could constrain internally funded growth, reduce the benefit of scale, and make future results more sensitive to product mix.

Falling Returns On EquityFalling returns on equity indicate that the expanding capital base has not produced proportionate profitability. Unless earnings improve, this trend suggests weaker capital efficiency and may limit the long-term value created from retained equity and balance-sheet growth.

Medicamen Biotech Limited News

Medicamen Biotech Gets NSE Caution Over Compliance Observations

The latest announcement is out from Medicamen Biotech Limited ( ($IN:MEDICAMEQ) ). Medicamen Biotech Limited has disclosed that...

7M ago

MEDICAMEQ FAQ

What was Medicamen Biotech Limited’s price range in the past 12 months?

Medicamen Biotech Limited lowest stock price was ₹210.10 and its highest was ₹454.00 in the past 12 months.

What is Medicamen Biotech Limited’s market cap?

Medicamen Biotech Limited’s market cap is ₹3.67B.

When is Medicamen Biotech Limited’s upcoming earnings report date?

Medicamen Biotech Limited’s upcoming earnings report date is Nov 06, 2026 which is in 59 days.

How were Medicamen Biotech Limited’s earnings last quarter?

Medicamen Biotech Limited released its earnings results on Aug 14, 2026. The company reported ₹1.562 earnings per share for the quarter.

Is Medicamen Biotech Limited overvalued?

According to Wall Street analysts Medicamen Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicamen Biotech Limited pay dividends?

Medicamen Biotech Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.36%. See more information on Medicamen Biotech Limited dividends here

What is Medicamen Biotech Limited’s EPS estimate?

Medicamen Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicamen Biotech Limited have?

Medicamen Biotech Limited has 13,562,815 shares outstanding.

What happened to Medicamen Biotech Limited’s price movement after its last earnings report?

Medicamen Biotech Limited reported an EPS of ₹1.562 in its last earnings report. Following the earnings report the stock price went down -0.824%.

Which hedge fund is a major shareholder of Medicamen Biotech Limited?

Currently, no hedge funds are holding shares in IN:MEDICAMEQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicamen Biotech Limited

Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is an Indian pharmaceutical firm primarily engaged in the manufacturing and distribution of a diverse range of medicinal formulations. Its product line encompasses various dosage formats, including tablets, capsules, liquid and dry syrups, and topical ointments. The company further extends its portfolio to specialized items such as oral rehydration solutions, mouthwashes, and dental care products.